AAD 2026Abstract 73498
Bimekizumab efficacy by disease duration and severity in moderate to severe hidradenitis suppurativa
3-year phase 3 results from BE HEARD EXT
Chovatiya R, Alavi A, Shi VY, van der Zee HH, Gooderham M, Miyagawa T, Zouboulis CC, Oh T, Crater C, Tilt N, Sabat R
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Hidradenitis suppurativa
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.332 · Not in PubMed: details from Crossref